- Home
- About Us
-
Investment Banking
- Equity Research
- Careers
- Contact
Equity Research
Rodman & Renshaw’s team of Research Analysts have achieved an enviable record of identifying compelling investment opportunities among undiscovered and undervalued companies. The Research Staff follows both industry leaders and emerging companies across a variety of sectors.
Our Team’s thoughtful research empowers a broad variety of Institutional Investors, including the world’s largest Asset Managers and Sector-dedicated Specialists throughout the U.S., Europe, Asia, and beyond.
Driven by Ph.D.’s and industry veterans, the Rodman Research Team understands both the business rationale and sector-specific dynamics around a value proposition – offering a comprehensive and competitive perspective. The Team’s work has been well-recognized across the Wall Street Journal, Financial Times, Institutional Investor, and other leading publications.
Michael G. King Jr.
Director of Research, Senior Biotechnology Analyst
Michael G. King Jr. is Director of Research and a Senior Biotechnology Analyst at Rodman & Renshaw. He brings more than 25 years of experience in biotechnology and healthcare equity research, advising investors and corporate management teams across market capitalizations and therapeutic categories. Over the course of his career, Mr. King has held senior research leadership roles at multiple Wall Street firms, including Bank of America, JMP Securities, and Robertson Stephens. He also previously served as Head of Research at Rodman & Renshaw from 2005 to 2009.
In addition to his sell-side research background, Mr. King has held operating and strategic roles within the biotechnology industry, including serving as Entrepreneur in Residence at Fortress Biotech and as Chief Financial Officer of SAB Biotherapeutics. He has been recognized for his work by The Wall Street Journal’s “Best on the Street” analyst survey and by Institutional Investor.
Mr. King earned a B.A. in Finance from the Bernard M. Baruch College of the City University of New York.
Seema Sheoran, Ph.D.
Vice President, Biotechnology Analyst
Seema Sheoran is a Biotechnology Equity Research Analyst at Rodman & Renshaw. She comes to the Firm from Evercore ISI, where she was a Vice President in Biotechnology Equity Research, contributing to coverage of small and mid-cap biotechnology companies across metabolic diseases (including MASH and obesity), immunology and inflammation, rare diseases, and infectious diseases. Prior to Evercore, Dr. Sheoran held biotechnology equity research roles at Jefferies and worked as a biotechnology analyst intern at Aspire Capital Partners.
Dr. Sheoran holds a PhD in Neuroscience and is the author of multiple peer-reviewed scientific publications, combining deep scientific training with public-markets experience to develop differentiated investment insights.
Coverage List
